Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ADARE-204 is a **long-acting injectable contraceptive** under development, designed to provide sustained release of **etonogestrel** for approximately 6 months. Its formulation utilizes **PLGA (poly(lactic-co-glycolic acid)) microspheres** to enable extended drug release, targeting a steady hormone dose and rapid return of fertility within two months after discontinuation. ADARE-204 aims to fill a need for contraceptive products that last between 3 months and 3 years, thereby enhancing options for women seeking reliable and convenient pregnancy prevention with minimal dependence on user adherence. The product is being developed through a collaboration between **Daré Bioscience** and **Adare Pharma Solutions**[5][6][7][11][12].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ADARE-204.